Fig. 11

Irinotecan inhibits cell growth and aerobic glycolysis via p53 signalling in HCT-116 cells. (A) Gene Set Enrichment Analysis (GSEA) plot illustrate the involvement of p53 signalling pathway from COAD dataset (GSE33113). (B) HCT-116 cells were subjected to treat with irinotecan with and without nut-3a cell viability was measured. (C and D) Glucose uptake and lactose production were measured by treating irinotecan and combing with nut-3a in HCT-116 cells. (E and F) ROS activity was also measured by evaluating the cellular SOD and CAT by treating irinotecan and nut-3a alone and in combined in HCT-116 cells. (G) cell cycle analysis by flow cytometry was measured by treating irinotecan with and without nut-3a in HCT-116 cells. (H) Cell death by Annexin V-FITC/PI double staining was measured by treatment of irinotecan and nut-3a in HCT-116 cells. (I) Gene expression of p53, p21, BAX, BCl2, LDHA, and GLUT2 was examined by RT-PCR by treating irinotecan and nut-3a alone and in combined in HCT-116 cells. Statistical significance: *p < 0.05, **p < 0.001, and ***p < 0.0001.